Kathy Hibbs

Kathy Hibbs is an accomplished health care technology executive and active board member with over two decades of expertise in health care and genomics. Kathy is the Chief Legal and Regulatory Officer of 23andMe, where she leads its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first ever FDA clearance for over-the-counter genetic testing. Regularly recognized as one of the Bay Area’s most influential women by the both the San Francisco and Silicon Valley Business Journals, Kathy is ranked by Chambers as among the most influential General Counsels in US. She sits on the boards of Decipher Biosciences, Inc. and Cadex Genomics Inc. During her 15 years’ experience as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX) and Monogram Biosciences, Inc. (NASDAQ: MGRM), Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated Summa Cum Laude from the University of California, Riverside and received her Juris Doctorate from Hastings College of the Law.